


List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1761046/publications.pdf Version: 2024-02-01



Ι ΔΡς ΒΑ

#	Article	IF	CITATIONS
1	Survival and cause of death in multiple sclerosis: a 60-year longitudinal population study. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 621-625.	1.9	180
2	Employment among Patients with Multiple Sclerosis-A Population Study. PLoS ONE, 2014, 9, e103317.	2.5	77
3	B cell depletion in the treatment of multiple sclerosis. Expert Opinion on Biological Therapy, 2019, 19, 261-271.	3.1	50
4	Deep Gray Matter Demyelination Detected by Magnetization Transfer Ratio in the Cuprizone Model. PLoS ONE, 2013, 8, e84162.	2.5	48
5	The cuprizone model: regional heterogeneity of pathology. Apmis, 2012, 120, 648-657.	2.0	36
6	Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis. BMC Research Notes, 2019, 12, 497.	1.4	35
7	Magnetization transfer ratio does not correlate to myelin content in the brain in the MOG-EAE mouse model. Neurochemistry International, 2015, 83-84, 28-40.	3.8	28
8	Fingolimod does not enhance cerebellar remyelination in the cuprizone model. Journal of Neuroimmunology, 2015, 285, 180-186.	2.3	22
9	Relationship Between White Matter Lesions and Gray Matter Atrophy in Multiple Sclerosis. Neurology, 2022, 98, .	1.1	21
10	Fingolimod downregulates brain sphingosine-1-phosphate receptor 1 levels but does not promote remyelination or neuroprotection in the cuprizone model. Journal of Neuroimmunology, 2020, 339, 577091.	2.3	18
11	Cuprizone and EAE mouse frontal cortex proteomics revealed proteins altered in multiple sclerosis. Scientific Reports, 2021, 11, 7174.	3.3	17
12	Botulinum Toxin as Monotherapy in Symptomatic Trigeminal Neuralgia. Headache, 2016, 56, 1035-1039.	3.9	16
13	Safety and efficacy of autologous hematopoietic stem cell transplantation for multiple sclerosis in Norway. Multiple Sclerosis Journal, 2020, 26, 1889-1897.	3.0	14
14	Impact of previous disease-modifying treatment on safety and efficacy in patients with MS treated with AHSCT. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 844-848.	1.9	11
15	Safety and efficacy of rituximab as first- and second line treatment in multiple sclerosis – A cohort study. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2021, 7, 205521732097304.	1.0	10
16	The effect of gadolinium-based contrast-agents on automated brain atrophy measurements by FreeSurfer in patients with multiple sclerosis. European Radiology, 2022, 32, 3576-3587.	4.5	4
17	A higher proportion of ermin-immunopositive oligodendrocytes in areas of remyelination. PLoS ONE, 2021, 16, e0256155.	2.5	2